In fifty-four patients with Alzheimer's disease [AD (14 males, 40 females, age 77 .1 2: 7.4 years)], free of any infection and twenty-two age-matched healthy controls with normal mental status (9 males, 13 females, age 74.9 ± 9.0 years) serum concentrations of soluble parameters of immune activation including neopterin, 55 kDa-type soluble tumor necrosis factor receptor (sTNF-RSS), soluble interleukin-2 receptor (sIL-2R), immunoglobulins A, M and G, complement components C3 and C4, circulating immune complexes, and soluble CD23 as well as a panel of routine laboratory tests were determined.
I n trod uction
The pathology of Alzheimer 's disease (AD) is :: h.lra.:terized by neurofibrillary tangles and senile plaques. In earlier studies the role of inflammation in AD was confirmed (1) . Reduced immune cell activity and abnormal concentrations of immune mediators \\'ere described in AD as well as in the healthy elderly (2) (3) (4) (5) (6) . The appearance of acute phase proteins (alanti chymotrypsin, C3, metallothionein) in the cortices of AD patients indicates ongoing immunopathological reactions in this neurodegenerative disorder (7, 8) . The synthesis of acute phase proteins is stimulated by cytokines such as interleukin-6, which was found immunohistochernically to be present in plaques of AD brains, indicating a cytokine-mediated process as part of the pathology of AD (9, 10) . Also signs of oxidatice stress and the presence of localized inflammatory autoimmune reactions in the brain .of patients with various neurodegenerative disorders has been documented (1, 11, 12, 13) . Oxidative damage could playa role in neurodegenerative diseases in general (11 , 14) . Earlier we have described abnormalities of serum soluble markers of immune activation in patients with neurodegenerative disorders (IS-17). The purpose of the current study was to confIrm and extend these fmdings in patients with AD. Serum concentrations of a panel of serum soluble immune parameters including neopterin, soluble receptors of interleukin-2 (sIL-2R) and tumor necrosis factor-a (55-kDa-type, sTNF-R5S), immunoglobulins and complement components were examined. Concentrations were compared to controls and to cognitive function measured by mini-mentalscore (MMS). Serum neopterin (BRAHMS Diagnostica, Berlin, Germany) soluble receptors, sTNF-R55 (Bender, Vienna, Austria) and sIL-2R, and soluble CD23 (sCD23) (T-Cell Sciences, Cambridge, MA) were measured by ELISA. Data were not normally distributed. Therefore, comparisons of grouped data were done by nonparametric Mann Whitney U-test. For analyses of correlations Spearman rank correlation coefficients were calculated using standard computer software.
Subjects and Methods

Results
There was no statistical difference in age between patients 77.1 ± 7.4 and 74.9 ± 9 .0 controls ( Table 2) .
Computed tomography showed diffuse cortical and subcortical atrophy without any focal lesion in AD patients. All routine laboratory tests were within normal limits, no laboratory signs of infection were seen. Compared to controls, a significant increase was found in AD patients for serum concentrations of sIL-2R (834 ± 583 versus 397 ± 213 IU/mI; P < 0 .01), neopterin (16.2 ± 9.7 versus 7 .6 ± 2.7 nM; P < 0.01) , sTNF-R55 (4.0 ± 2.1 versus 2.9 ± 1.4 ng/mI; p < 0.05) and sCD23 (122:t 124 versus 71 ± 40 IU/ml; p < 0.05), and also IgA (356 ± 166 versus 260 :t 126 mg/dl; p < 0.05) but not for IgM and IgG (Fig. 1 ) . A trend to higher C3 levels (p = 0.071) was found in the patients, C4 concentrations did not differ between patients and controls.
In the patients average MMS was 10.4 ± 7.5. Patients with lower MMS had higher sTNF-R55, neopterin and sIL-2R concentrations than those with higher MMS (Table 2 ). Significant correlations were found between MMS and sTNF-R55 (rs = -0.447; P < 0.01) as well as neopterin (rs = -0.289; P < 0.05). No significant correlations existed between MMS and sIL-2R and between in'lmune activation parameters and the duration of the disease. Significant correlations were found between neopterin and sTNF-R55 (rs = 0.649, p < 0.01) and sIL-2R (rs = 0 .588, p < 0 .01) concentrations. 
Discussion
The pathogenesis of AD is still unknown. AD is characterized by gradually progressing neuropsychiatric manifestations, and there are data indicating th.at excitotoxicity and oxidative damage could be involved (11) . Stimulated immunocompetent cells are an important source of reactive oxygen species, and several studies have shown altered cell -mediated unmunity in the peripheral blood of patients with AD (2, (20) (21) (22) (23) . These previous fmdings of a peripheral immune dysregulation in AD are underscored by our data. Significantly increased serum levels of neopterin and the soluble receptors sIL-2R and sTNF-R55, sCD23 and IgA were found. A trend to higher C3 values indicates an activation of the complement cascade (I) in our patients with AD. This relationship is strikingly similar to that found in other long-lasting disorders like malignancy, infections or autoimmune diseases. Increased concentrations of neopterin are produced and released from activated human monocytes/macrophages upon stimulation with interferon-y and therefore are indicative for an activated cellular immune system (24) . Increased neopterin concentrations have been described earlier in patients with infections preferentially of viral origin, in autoimmune disorders, in certain types of cancer and during rejection episodes in allograft recipients (for a review see ref. 24) , Especially in patients with mv -I infection but also in cancer higher neopterin concentrations have been found to be PteridinesIVol. IIINo. 2 associated with more rapid disease progression and shortened survival (25, 26) . In patients with cerebral infections, extremely high neopterin concentrations have been found in the CSF (27) , e.g., in patients with Lyme neuroborreliosis CSF neopterin concentrations sometimes exceeded 100 nM whereas serum levels still remained within the normal range « 8.7 oM; ref. 28 ).
By contrast, in severely ill patients with different forms of amyotrophic lateral sclerosis (ALS) increased neopterin concentrations were found neither in the CSF nor in the serum (29) . This fmding may serve as an argument that low levels of activity or living in a caretaking facility as it is true in some of the patients with AD but also in ALS is not responsible for the increased concentrations of immune activation parameters seen in the patients with AD. Increased conc otrations of soluble cytokine receptors, sTNF-R55 and sIL-2R, also give evidence for an activated immune system in our patients, because also these compounds are mainly products of immunocompetent cells like macrophages and Tlymphocytes stimulated by specific cytokines (30, 31) . Increased concentrations of sCD23 and IgA suggest non-specific activation of the humoral immune system in parallel (32), Thus, it seems that deviations of several immune compartments occur in AD. However, this observations are only relevant for the periphery, and not the central nervous system. Measurement of cytokines like interleukin-Il3, interleukin-6, TNF-a, and interferons in the blood or CSF of patients with AD led interferons in the blood of CSF of patients with AD led to contradicting results, some studies showing increased (33 -38) others normal (33, 38 -40) concentrations, This may be partly due to the fact that measurement of cytokine concentrations is often limited by their biological half-life and by their strong affInity to receptors either on target cells or their soluble forms in the extracellular space (30), so they may not suffIciently penetrate from their production site into body fluids. In contrast, e.g., neopterin is biologically stable and once produced it penetrates quickly into body fluids and thus allows a more reliable insight into the actual activation state of the cellular immune system. The production of neopterin in the brain may however depend on the presence of monocytic cells (27) . The mechanisms underlying the immunological lbnormalities in AD remains unclear. Importantly, the changes of soluble immune parameters were detected in sera of patients, and all patients were free of any clinical and laboratory sign of infection, e.g. all had normal concentrations of C-reactive protein. Concentrations of 50me of the immune parameters were measured in a few of our patients in cerebrospinal fluid (CSF) and serum in parallel, and CSF concentrations were often increased compared to control levels (data not shown), ':Jut in almost all cases serum concentrations were higher than those in CSF. Thus, intrathecal production of the parameters cannot account for the alterations seen in the serum. These data imply that peripheral activation of the immune system could be important in the course of AD. On the other hand, in AD, CSF may not contain a high enough cell count capable of actively synthesizing the immune parameters as does serum. 1bis could also explain why lower concentrations of soluble immune parameters are found in the serum than in the CSF of patients with AD. Similarly we found increased serum concentrations of , e.g., neopterin also in patients with Huntington's disease (16) and in a patient with Creutzfeldt-lakob's disease (34) to be associated with low serum levels. Increased neopterin levels together with increased sTNF-R55 and sIL-2R imply a chronic state of cellular immune activation in AD patients and support the hypothesis of immune-mediated mechanisms as a part of the pathogenesis of AD. Disruption of the blood brain barrier may be important (1), and blood brain barrier impairment may be associated with or even be caused by a general immune activation (41) . Peripheral immune activation could provide a basis for activated immunocompetent cells to invade through the blood brain barrier and also to transfer reactive compounds into the brain to keep going an inflammatory process and oxidative stress. Although there seems to be no evidence for this, it seems possible that the degenerating process in the brain could also be fed by the peripheral immune activation process. At least it is an astonishing fmding that the concentrations of immune parameters in serum correlate with the cognitive capability of patients with AD. Numerous cytokines such as interleukin-l, interleukin-2, interleukin-6 and TNF-a have been shown to directly affect brain activity (9, 23, 35) . Brain injury, a risk factor for AD, is associated with increased IL-l and increased APP-synthesis (42) . It seems also possible that peripberal immune activation could contribute to altered APP metabolism. APP is considered to be an acute phase protein itself, the expression of which is influenced by a number of cytokines, which may be an important event in the amyloidogenesis of AD patients (8, 14) . Interestingly, APP is upregulated in peripheral mononuclear cells upon activation (43) . Our data would support the hypothesis that AD is an immunologically derived disease with clinical effects confmed primarily to the brain (44) , but it may lead also to systemic immune abnormalities. Peripheral immune activation could provide an explanation for the clustering of autoimmune diseases in patients with AD (45) and agree well with beneficial effect of anti-inflammatory drugs in these patients (1, 46, 47) . Recent studies also demonstrate the role of the peripheral immune system in cognitive impairment and dementia (48) .
In conclusion, our data show a significantly increased activation status of the immune system in the periphery of patients with AD. 1bis fmding is not specific to patients with AD or neurodegenerative disorders and t.~ere is significant overlap of the concentrations of immune system-derived parameters measured in patients and controls. Therefore measurement of these parameters cannot be of any diagnostic relevance, although it may present an easier assessment of the course of the disease. Follow up studies will be necessary to clarify this issue. The data show some new aspects which could be of relevance for the course of the disease of patients with AD. In earlier studies low concentrations of neopterin have been described in CSF (49) and blood (50) of patients with Alzheimer's disease. At fIrst glance, our data seem to contradict these findings. Since increased age is accompanied with increasing neopterin concentrations and the impact of Alzheimer's disease on neopterin concentrations is only an additional effect (51) . Since older age is very often associated with inflammatory conditions, it will depend on the composition of the control group whether still higher neopterin concentrations can be detected in the patients with Alzheimer's disease. On the other hand, the associations found between neopterin concentrations and other markers of immune activation further support the view that there is an increased production of neopterin due to immune system activation, which however seems to be more expressed in the peripheral blood than in the CSF.
